PD-1 resistance is expected to be solved! TIM-3 Target approved clinical, Hengrui, BMS, Roche latest progress...
Time of Update: 2020-07-10
Introduction: PD-1/L1 first echelon, competition for new directions foreword: Recently, Novartis in the study of TIM-3 monoclonal antibody MBG453 obtained a clinical trial license, and this antibody has high hopes that it may become
Merthyr's heavy anti-PD-1 cancer immunotherapy Keytruda Phase 3 clinical trial reaches major endpoint
Time of Update: 2020-06-11
Today, The of The of Mercadon (announced that the company's heavy-duty anti-PD-1 cancer immunotherapy Keytruda, as a second-line therapy, reached the primary end of the phase 3 clinical trial in patients with advanced
First-line treatment of lung cancer Sanofi / regenerative meta-PD-1 inhibitor phase 3 clinical data positive
Time of Update: 2020-06-01
In addition, Libtayo is treating patients with cervical cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma and non-Hodgkin lymphoma in clinical trials.
Primary end point of treatment of NSCLC with PD-1 antibody of Baiji Shenzhou of "medical fast reading society" reached 3 stages
Time of Update: 2020-01-22
[January 22, 2020 / medical information list] patients with new pneumonia can enjoy special reimbursement policies; Nanyan technology has completed a round of financing of more
New medical insurance era: PD-1 price has not yet bottomed out? How will the 4 + 3 competition
Time of Update: 2020-01-07
"Chinese companies are very vulnerable when it comes to health care negotiations, because there is no other market to take on the cost, so they've saved their lives." On January 5
Research and development daily, Baiji Shenzhou PD-1 review status update, Xinda Biology 3 new drugs approved
Time of Update: 2019-11-15
On November 14, amarin announced that the FDA expert advisory committee voted 16:0 to approve vascepa as a new indication for reducing cardiovascular risk.
Positive phase 3 clinical data of Sanofi / regenerant PD-1 inhibitor in the first-line treatment of lung cancer
Time of Update: 2019-11-07
Recently, regeneron announced that the mid-term data analysis showed that libtayo, a PD-1 inhibitor jointly developed with Sanofi, as a single drug therapy, showed significantly
Immunotherapy for stage III lung cancer! AstraZeneca PD-L1 tumor immunotherapy imfinzi US label update, 3-year survival rate 57%
Time of Update: 2019-07-23
July 23, 2019 / BIOON / - AstraZeneca, a British pharmaceutical giant, recently announced that the US Food and Drug Administration (FDA) has approved the treatment of PD-L1 tumor
Hengrui PD-L1 monoclonal antibody shr-1316 will enter clinical phase 3, and will be on the market soon
Time of Update: 2018-12-05
On December 4, Hengrui pharmaceutical announced that the company and its subsidiary Shanghai Hengrui pharmaceutical will carry out the phase III clinical trial of shr-1316 injection in the near future.
The latest priority review list will be publicized and 3 domestic PD-1 varieties will be listed!
Time of Update: 2018-04-24
Source: from April 23, 2018 to April 24, 2018, the CDE official website released the public list of the 28th batch of drug registration applications to be included in the priority
The latest proposed priority review list announced 3 domestic PD-1 varieties in the column!
Time of Update: 2018-04-24
Medicines Network April 24 - On April 23, cDE's official website published the 28th batch of drug registration applications to be included in the priority review process public list. Several of the recent lying PD-1 varieties are on the list
Delivery |, targeting PD-1 and LAG-3 at the same time, double specific new drugs enter the clinical
Time of Update: 2017-09-11
At the same time, macrogenomics has submitted an ind application for another new drug, mgd014, which can target HIV infected cells and T cells carrying CD3 antigen at the same time.
Significantly reduce the risk of lung cancer! AZ anti PD-L1 drug phase 3 was a great success
Time of Update: 2017-05-15
Source: the field of cancer immunotherapy of Wuxi apptec on May 15, 2017 has seen a surge in recent years
This week, a new anti PD-L1 drug jointly developed by Merck